Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 642 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oral Sodium Chloride Clear all
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

NCT02369159
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
0 Days to 17 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Shreveport, Louisiana • Dayton, Ohio • Smithfield, Pennsylvania + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

Intravesical Cidofovir for Hemorrhagic Cystitis

NCT01816646
View directory record Official record
Conditions
Blood And Marrow Transplantation
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

NCT02873819
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo
Drug
Lead sponsor
Gliknik Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

NCT00527761
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Cisplatin, Docetaxel, Temodar
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 2, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

NCT00910039
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, cognitive assessment
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 2, 2026, 9:43 AM EDT
Terminated Early Phase 1 Interventional

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

NCT04968951
View directory record Official record
Conditions
Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions
Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation
Drug · Biological
Lead sponsor
Ari M Grinspan
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 2, 2026, 9:43 AM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 2, 2026, 9:43 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

NCT03077477
View directory record Official record
Conditions
Neoplasms, Medication Toxicity, Tolerance
Interventions
AMXT 1501, Placebo Oral Tablet
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 2, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device)
Drug · Device
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Hygiene Intervention Pilot Study

NCT02668809
View directory record Official record
Conditions
Dental Caries, Gingivitis
Interventions
oral health assessment, Questionnaires, Clinical Exam, Microbiological sampling, Monitoring Adherence, Varnish application, Consent, Educational Program
Other
Lead sponsor
Leonardo Marchini
Other
Eligibility
21 Years to 120 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients

NCT03938584
View directory record Official record
Conditions
Vitamin C Deficiency, Smoking, Surgery, Surgery--Complications, Wound, Wound Complication, Wound Infection, Wound Dehiscence, Wound of Skin, Mandible Fracture, Mandible Open Fracture, Mandible Closed Fracture, Mandibular Fractures, Ascorbic Acid Deficiency, Oxidative Stress, Inflammation
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NCT02412761
View directory record Official record
Conditions
Essential Hypertension
Interventions
Lisinopril, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 22 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
IV Ganciclovir, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

NCT01185171
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ZD 1839 500mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 2, 2026, 9:43 AM EDT
Terminated Phase 1 Interventional Results available

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

NCT03594487
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
Drug · Procedure · Other
Lead sponsor
Jeffrey Gelfand
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

NCT02532764
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
QR-010, Placebo
Drug
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 2, 2026, 9:43 AM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

NCT01702493
View directory record Official record
Conditions
Psoriasis
Interventions
Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871
View directory record Official record
Conditions
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Apremilast, Etanercept, Placebo tablet, Placebo injection
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

NCT02100631
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
46 Years to 64 Years
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
16
States / cities
Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 2, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

NCT00606502
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pralatrexate, Erlotinib, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Port Saint Lucie, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 2, 2026, 9:43 AM EDT